Home Equities Score Aridis Pharmaceuticals Inc. (ARDS) stock plunges during current market. Here’s the update

Aridis Pharmaceuticals Inc. (ARDS) stock plunges during current market. Here’s the update

Aridis Pharmaceuticals Inc. (NASDAQ: ARDS) stock declines during the current market by 11.11%. Aridis Pharmaceuticals, Inc. researches and develops anti-infectives that can be used in conjunction with conventional antibiotics to treat infections.

Current Development

Aridis Pharmaceuticals has signed an exclusive, global licensing deal with AstraZeneca to in-license suvratoxumab, a late-stage monoclonal antibody product.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


The following are the key points of the contract:

  • Candidate for Phase 3 AstraZeneca has licensed Suvratoxumab, a monoclonal antibody (mAb) for the prevention of pneumonia. Suvratoxumab complements Aridis’ current AR-301 Phase 3 pneumonia therapy development, extending the company’s pneumonia business.
  • This is a Lancet ID publication. Protection and a statistical significance (47 percent) relative decrease of pneumonia in S. aureus colonized, mechanically ventilated patients less than 65 years old were authored in The Lancet Infectious Diseases journal, with correlating decrease in the amount of days needed in the ICU and hospital.
  • Up to €25 million in financing (about $30 million) is available. Suvratoxumab Phase 3 clinical trial is being funded by the EU Commission’s Innovative Medicines Initiatives.
  • The ownership interest in Aridis held by AstraZeneca. Through the issuing of common stock, AstraZeneca becomes a stakeholder of Aridis and has the right of first negotiation for future licensing

Official Statements

Vu Truong, Aridis’ Chief Executive Officer stated,

They are honored to be chosen as AstraZeneca’s licensee. The excellent findings from the Phase 2 trial offer them an edge in defining the patient group, main endpoint, and clinical study design for the Phase 3 confirmatory trial, paving the way for a clear route to the Phase 3 confirmatory trial.

Mark Esser, Vice President, Microbial Sciences, AstraZeneca commented,

Suvratoxumab has the potential to revolutionize the treatment of lung infections in ventilated patients. They are happy to finalize this licensing agreement with Aridis, who they feel will be a strong partner in the development of suvratoxumab.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Must Read

Energous Corporation Inc. (WATT) stock declines during after-market. Here’s to know why?

Energous Corporation Inc. (WATT) stock gained by 7.05% at last close whereas the WATT stock price plunged by 7.82% in the after-hours trading session....

AMAZON Inc. (AMZN) stock fell during after-market. Here’s the update

Amazon Inc. (NASDAQ: AMZN) stock plunged by 0.84% at last close however moving ahead the AMZAN share price also declines by 7.44% in the...

Cocrystal Pharma Inc. (COCP) stock soars during current market. Here’s what you should know

Cocrystal Pharma Inc. (NASDAQ: COCP) stock gains by 17.44% in the current market trading session. Cocrystal Pharma, Inc. is a clinical-stage biotechnology firm focused...

Why did Corvus Pharmaceuticals Inc. (CRVS) stock soar on Wednesday?

Corvus Pharmaceuticals Inc. (CRVS) shares surged 9.17% in after-hours on Wednesday, July 28, 2021, and closed the daily trading at $2.38. in the regular...

Havertys Furniture Companies Inc. (HVT) stock gains during after-hour trading, Here’s to know why?

Havertys Furniture Companies Inc. (NASDAQ: HVT) stock declined by 0.39% at last close whereas the HVT stock price gains by 4.6% in the after-hours...

ImmunoPrecise Inc. (IPA) stock fell during pre-market. What’s the update?

ImmunoPrecise Inc. (NASDAQ: IPA) stock declined by 8.39% at last close while the IPA stock-price plunge by 4.87% in pre-market as well. ImmunoPrecise is...

ECMOHO Ltd. (MOHO) stock plunged during pre-market. Let’s see what’s happening?

ECMOHO Ltd. (NASDAQ: MOHO) stock gained by 7.05% at last close, while during pre-market MOHO stock has been seen declining by 7.75%. In China's...

Synthetic Biologics Inc. (SYN) stock plunged during pre-market. Here’s what you should know?

Synthetic Biologics Inc. (NASDAQ: SYN) stock gained by 8.09% at last close whereas the SYN stock price declines by 0.54% in the pre-market trading....

Related News

UXIN stock declines during current market trading. What’s driving it low?

Uxin Ltd. (NASDAQ: UXIN) stock declines by 3.41% during current market trading. In China, Uxin Limited is a prominent online used vehicle dealer with...

Synthetic Biologics Inc. (SYN) stock plunged during pre-market. Here’s what you should know?

Synthetic Biologics Inc. (NASDAQ: SYN) stock gained by 8.09% at last close whereas the SYN stock price declines by 0.54% in the pre-market trading....

Why did Atossa Therapeutics Inc. (ATOS) underperform on Thursday?

Atossa Therapeutics Inc. (ATOS) shares fell 5.38% in after-hours on Thursday, July 29, 2021, and closed the daily trading at $3.69 per share. Earlier...

Why Ardelyx Inc. (ARDX) stock price fluctuated on Thursday?

Ardelyx Inc. (ARDX) shares jumped 2.92% in after-hours on Thursday, July 29, 2021, and closed the daily trading at $1.76. Earlier in the regular...

Annovis Bio Inc. (ANVS) stock plunged during current market. Here’s the update

Annovis Bio Inc. (NASDAQ: ANVS) stock declined by 51.30% in the current market trading session. Annovis Bio based in Berwyn, Pennsylvania, is a clinical-stage...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam